Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
In a recent study, researchers found that radiation therapy to the whole brain after radiosurgery for cancer that has spread to the brain causes more thought and memory problems than just radiosurgery. Even though the additional radiation therapy controlled the cancer’s growth, it did not lengthen patients’ lives.
A new study provides clarification on the best time for patients to receive lymph node surgery for early-stage oral cancer.
Recently, researchers found that nivolumab (Opdivo) either given as a single treatment or in combination with ipilimumab (Yervoy) is more effective than treatment with ipilimumab alone for people with advanced melanoma.
A recent analysis of information from more than 34,000 children who participated in the Childhood Cancer Survivor Study shows that modern cancer care is reducing deaths from cancer and long-term side effects.
According to the results of a recent study, people who have surgery to remove lymph nodes near a melanoma tumor live the same amount of time as those who are watched closely for signs of cancer.
Approximately 12,000 people will be diagnosed with a soft-tissue sarcoma in the United States this year. Currently, there are few treatment options available, especially for tumors that grow or spread to other parts of the body during treatment. However, recent research has shown that the chemotherapy eribulin (Halaven) may be a promising new treatment option for people with two types of rare soft-tissue sarcomas: leiomyosarcoma and adipocytic sarcoma, which is also called liposarcoma.
In a large, ongoing study, researchers found that a combination of ibrutinib (Imbruvica) and standard treatment slows the growth of chronic lymphocytic leukemia (CLL) and lowers patients’ risk of dying from the disease.
A large clinical trial suggests that anastrazole (Arimidex) may be a new option for preventing breast cancer after treatment for ductal carcinoma in situ (DCIS). DCIS is a non-invasive type of breast cancer. DCIS can usually be eliminated with a lumpectomy followed by radiation therapy. However, women with DCIS are at increased risk for developing invasive breast cancer in the same or opposite breast.
A recent study showed that the drug pacritinib works better for myelofibrosis than current treatments.
A large phase III study has found that a new targeted therapy, called palbociclib (Ibrance), delayed the growth and spread of advanced hormone receptor-positive breast cancer by roughly five months when combined with the standard hormonal therapy fulvestrant (Faslodex). This combination could become a new treatment option for women with hormone receptor-positive, HER2-negative breast cancer that has spread to other parts of the body.